Abivax (ABVX) Common Equity: 2023-2025
Historic Common Equity for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to $54.7 million.
- Abivax's Common Equity rose 140.13% to $54.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $54.7 million, marking a year-over-year increase of 140.13%. This contributed to the annual value of $43.4 million for FY2024, which is 79.44% down from last year.
- Per Abivax's latest filing, its Common Equity stood at $54.7 million for Q2 2025, which was up 888.16% from -$6.9 million recorded in Q1 2025.
- In the past 5 years, Abivax's Common Equity registered a high of $210.9 million during Q4 2023, and its lowest value of -$136.2 million during Q2 2024.
- Its 3-year average for Common Equity is $56.4 million, with a median of $49.0 million in 2025.
- Examining YoY changes over the last 5 years, Abivax's Common Equity showed a top increase of 140.13% in 2025 and a maximum decrease of 104.02% in 2025.
- Over the past 3 years, Abivax's Common Equity (Quarterly) stood at $210.9 million in 2023, then crashed by 79.44% to $43.4 million in 2024, then skyrocketed by 140.13% to $54.7 million in 2025.
- Its Common Equity was $54.7 million in Q2 2025, compared to -$6.9 million in Q1 2025 and $43.4 million in Q4 2024.